LONG MINI FUTURE - ELI LILLY & CO | Market Closed - Swiss Exchange 11:20:00 2024-05-10 am EDT | ||
| 2.53 CHF | -1.94% |
|
| Current month | -2.69% | ||
| 1 month | +0.80% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 2.53 | -1.94% | 0 |
| 24-05-08 | 2.58 | +0.78% | 0 |
| 24-05-07 | 2.56 | +7.11% | 0 |
| 24-05-06 | 2.39 | +9.13% | 0 |
| 24-05-03 | 2.19 | -13.78% | 0 |
Delayed Quote Swiss Exchange
Last update May 10, 2024 at 11:20 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| MLLAEV | |
| ISIN | CH1290585376 |
| Date issued | 2023-08-31 |
| Strike | 490.8 $ |
| Maturity | Unlimited |
| Parity | 100 : 1 |
| Emission price | 0.8 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 2.74 CHF |
|---|---|
| Lowest since issue | 0.55 CHF |
| Spread | 0.01 CHF |
| Spread % | 0.40% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
760
USD
Average target price
850.4
USD
Spread / Average Target
+11.90%
- Stock Market
- Certificates
- MLLAEV Certificat